Glucosio Con Potassio Cloruro Baxter

Glucosio con Potassio Cloruro Baxter is an injectable solution that combines potassium chloride and glucose. It is supplied as a sterile liquid for intravenous administration and is classified as an electrolyte replacement therapy. The product is marketed in the European Union and requires a prescription. It is used to restore potassium levels and provide an energy source during fluid therapy. The formulation allows rapid correction of low potassium.

Glucosio con Potassio Cloruro Baxter is indicated for several clinical situations where potassium replacement and fluid balance are required.

- Treatment of hypokalemia (low blood potassium). - Electrolyte replacement during surgery or intensive care. - Fluid therapy for patients unable to maintain oral intake. - Prevention of potassium deficiency in patients receiving diuretics. - Support of intracellular potassium shift during glucose infusion in metabolic emergencies. - Use in combination with other electrolytes for comprehensive rehydration protocols.

Adverse reactions to Glucosio con Potassio Cloruro Baxter are generally related to the intravenous administration of electrolytes and glucose.

Common: - Injection site pain or erythema. - Transient hyperglycemia. - Mild nausea. - Temporary increase in serum potassium within therapeutic range. - Mild headache. - Mild dizziness. - Slight increase in urine output. - Mild flushing or warmth sensation. - Temporary rise in serum osmolality.

Serious: - Severe hyperkalemia leading to cardiac arrhythmia. - Anaphylactic or severe allergic reaction. - Rapid rise in blood glucose causing osmotic diuresis. - Phlebitis or thrombophlebitis at infusion site. - Electrolyte imbalance causing muscle weakness or paralysis. - Severe metabolic acidosis in patients with renal impairment. - Cardiac arrest due to uncontrolled hyperkalemia.

Before administering Glucosio con Potassio Cloruro Baxter, clinicians should evaluate patient-specific factors and monitor relevant parameters to reduce risk.

- Assess serum potassium and glucose levels prior to infusion. - Verify renal function, especially in patients with chronic kidney disease. - Adjust infusion rate in patients at risk of cardiac arrhythmias. - Avoid rapid administration in patients with known hypersensitivity to potassium chloride or glucose. - Monitor cardiac rhythm and blood pressure during and after infusion. - Use caution in patients receiving insulin or other agents that shift potassium intracellularly. - Ensure proper aseptic technique to prevent infection at the injection site.

Glucosio con Potassio Cloruro Baxter may interact with other medications that affect potassium balance, glucose metabolism, or cardiac conduction.

Avoid: - Concomitant use with other potassium salts or high‑potassium diets without monitoring. - Simultaneous administration of rapid‑acting insulin without glucose monitoring. - Co‑administration with calcium channel blockers that prolong the QT interval in high doses.

Use with caution: - Diuretics that cause potassium loss (e.g., loop or thiazide diuretics) – monitor levels closely. - ACE inhibitors or ARBs – may increase serum potassium. - Beta‑adrenergic agonists – can shift potassium intracellularly. - Sodium bicarbonate therapy – may affect potassium distribution. - Digitalis glycosides – risk of enhanced cardiotoxicity with elevated potassium.